Table 3.
Comparison between patients wit Systemic Lupus Erythematosus with abnormal TyG index and normal TyG index
| Variables | SLE Abnormal TyG Index n = 28 |
SLE Normal TyG index n = 29 |
p |
|---|---|---|---|
| Age (yrs) mean ± SD | 47.1 ± 11 | 46.5 ± 8.6 | 0.8 |
| Disease duration (years), mean ± SD | 13.0 ± 7.7 | 11.2 ± 7.7 | 0.2 |
| Smoking, n (%) | 4 (14.3) | 5 (17.2) | 1.0 |
| Sedentary lifestyle, n (%) | 13 (46.4) | 20 (69) | 0.08 |
| Hypertension, n (%) | 10 (35.7) | 6 (20.7) | 0.2 |
| Duration of hypertension (years), mean ± SD | 3.0 ± 6.4 | 1.1 ± 4.8 | 0.06 |
| Menopause, n (%) | 15 (53.6) | 15 (51.7) | 0.8 |
| Body mass index (kg/m2), mean ± SD | 30.0 ± 5.1 | 28.1 ± 5.1 | 0.1 |
| Waist (cm), mean ± SD | 96.9 ± 12.8 | 88.7 ± 13.8 | 0.02 |
| Total-cholesterol (mg/dL), mean ± SD | 214.7 ± 42.9 | 181.0 ± 31.6 | 0.001 |
| Total-cholesterol (mmol/L), mean ± SD | 5.5 ± 1.1 | 4.6 ± 0.8 | 0.001 |
| HDL-cholesterol (mg/dL), mean ± SD | 49.8 ± 14.2 | 54.2 ± 14.9 | 0.2 |
| HDL-cholesterol (mmol/L), mean ± SD | 1.2 ± 0.3 | 1.4 ± 0.3 | 0.2 |
| LDL-cholesterol (mg/dL), mean ± SD | 123.9 ± 35.1 | 108.0 ± 24.6 | 0.05 |
| LDL-cholesterol (mmol/L), mean ± SD | 3.2 ± 0.9 | 2.7 ± 0.6 | 0.05 |
| Uric Acid(mg/dL), mean ± SD | 5.0 ± 1.2 | 4.3 ± 0.9 | 0.01 |
| Uric Acid(mmol/L), mean ± SD | 2.9 ± 0.7 | 2.5 ± 0.5 | 0.01 |
| Fat mass% (DXA results), mean ± SD | 50.2 ± 4.5 | 46.7 ± 4.4 | 0.007 |
| Treatments | |||
| Corticosteroid, n (%) | 28 (100) | 26 (89.6) | 0.2 |
| Chloroquine, n (%) | 13 (46.8) | 13 (44.8) | 1.0 |
| Methotrexate, n (%) | 4 (14.3) | 5 (17.2) | 1.0 |
| Leflunomide, n (%) | 2 (7.1) | 3 (10.3) | 1.0 |
| Biologics, n (%) | 7 (25) | 6 (20.7) | 0.6 |
Italic values indicate significance of p value (p < 0.05)
An abnormal TyG index (TyG index > 4.68) suggests insulin resistance; HDL-cholesterol high density lipoprotein-cholesterol, LDL-cholesterol low density lipoprotein-cholesterol, DXA dual-energy X-ray absortiometry; TyG values are expressed in mean and standard deviation SD; comparisons between proportions were calculated by Χ2 test or Fisher´s exact test; comparisons between means by unpaired Student-t test; biologics included in the analysis: adalimumab, rituximab, infliximab